Description

AptarGroup: The Hidden Turnaround In Beauty, Closures, & High-Value Pharma Innovation!

AptarGroup, Inc. reported first-quarter 2026 results reflecting a stable but mixed operating environment amid ongoing portfolio and market dynamics. Reported sales increased by 11%, positively influenced by favorable currency movements, while core sales—adjusted for currency and acquisitions—remained flat year-over-year. Adjusted EBITDA rose 3% to $189 million; however, the adjusted EBITDA margin contracted to 19.2% from 20.7% in the prior year, attributed mainly to less favorable product mix and operational challenges in the Beauty and Closures segments. Adjusted earnings per share declined to $1.19 from $1.30 at comparable exchange rates. Within the Pharma segment, core sales declined slightly by 1%, primarily driven by a 3% decrease due to anticipated destocking in emergency medicine dispensing systems—a $65 million full-year impact anticipated to mostly occur during the first half of 2026.